The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC): Safety results.
W. Janni
Consultant or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; GlaxoSmithKline; Novartis; Pfizer; Roche; Sanofi
Honoraria - AstraZeneca; Bayer; Chugai Pharma; GlaxoSmithKline; Novartis; Pfizer; Roche; Sanofi
Research Funding - AstraZeneca; Bayer; Chugai Pharma; GlaxoSmithKline; Novartis; Pfizer; Roche; Sanofi
T. Sarosiek
Honoraria - GlaxoSmithKline (B)
Research Funding - GlaxoSmithKline (B)
C. A. Papadimitriou
No relevant relationships to disclose
J. V. Álvarez Gallego
No relevant relationships to disclose
M. Caruso
No relevant relationships to disclose
W. Wiest
No relevant relationships to disclose
M. L. Lim
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
H. Andersson
No relevant relationships to disclose
A. Das-Gupta
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline